March 20, 2015Journal of Hypertension
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
Key result
In hypertensive patients with atrial fibrillation and left ventricular hypertrophy, digoxin use was not associated with an increased risk of all-cause mortality (HR 1.04; 95% CI 0.73-1.48; P=0.839).
Why the study?
Does digoxin use increase all-cause mortality in hypertensive patients with atrial fibrillation and left ventricular hypertrophy?
Population
937 hypertensive patients with ECG left ventricular hypertrophy and atrial fibrillation from the LIFE trial
Comparison
In-treatment digoxin use vs No digoxin use
Design
Cohort, Patients were randomly assigned to losartan or atenolol-based treatment
Follow-up
mean 4.7 ± 1.1 years
Authors
Discussion
Loading...
Member takes
Implication
Adds observational safety data on digoxin; leaves open randomized confirmation in hypertensive AF with LVH.
Study Design
Type
Cohort (n=937)
Structured PICO
Does digoxin use increase all-cause mortality in hypertensive patients with atrial fibrillation and left ventricular hypertrophy?
P
Population
937 hypertensive patients with ECG left ventricular hypertrophy and existing or new atrial fibrillation, followed for a mean of 4.7 years.
E
Exposure
In-treatment digoxin use
C
Comparator
No digoxin use
O
Outcome
All-cause mortalityhard clinical
Main Result
Hazard Ratio: 1.04 (95% CI 0.73–1.48)
p-value: p=0.839
In hypertensive patients with atrial fibrillation and left ventricular hypertrophy, digoxin use is not associated with increased all-cause mortality after adjusting for confounders and propensity to use digoxin.
Cite This Study
Okin et al. (2015) conducted a cohort in Hypertension with atrial fibrillation and left ventricular hypertrophy (n=937). Digoxin use vs. No digoxin use was evaluated on All-cause mortality (HR 1.04, 95% CI 0.73-1.48, p=0.839). In hypertensive patients with atrial fibrillation and left ventricular hypertrophy, digoxin use was not associated with an increased risk of all-cause mortality (HR 1.04; 95% CI 0.73-1.48; P=0.839).